Drug Profile
Skeletal muscle-derived autologous stem cell therapy - Fina Biotech
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Fina Biotech
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 19 Mar 2019 Discontinued - Phase-II for Myocardial infarction in Spain (Intracardiac)